• Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, Warnes TW 2003 Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim. Biophys. Acta 1637: 142-150. *

• Adler M, De Gendt E, Vereerstraeten P, Degre D, Bourgeois N, Boon N, Gelin M, Ickx B, Donckier V 2005 Value of the MELD score for the assessment of pre- and post-liver transplantation survival. Transplant. Proc. 37: 2863-2864. *

• Afessa B, Kubilis PS 2000 Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am. J. Gastroenterol. 95: 484-489. *

• Akinci B, Comlekci A, Tankurt E 2008 Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Exp. Clin. Endocrinol. Diabetes Jun 17 [Epub ahead of print].

• Alam I, Bass NM, Bacchetti P, Gee L, Rockey DC 2000 Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am. J. Gastroenterol. 95: 199-203. *

• Alkari B, Shaath NM, El-Dhuwaib Y, Aboutwerat A, Warnes TW, Chalmers N, Ammori BJ 2005 Transjugular intrahepatic porto-systemic shunt and variceal embolisation in the management of bleeding stomal varices. Int. J. Colorectal Dis. 20: 457-462. *

• Andriulli A, de Sio I, Solmi L, De Carlis L, Troisi R, Grasso A, Festa V, Caturelli E, Giacomoni A, Del Vecchio Blanco C, De Hemptinne B, Burroughs A, Perri F 2004 Survival of cirrhotic patients with early hepatocellular carcinoma treated by percutaneous ethanol injection or liver transplantation. Liver Transpl. 10: 1355-1363. *

• Angelico M, Gandin C, Nistri A, Baiocchi L, Capocaccia L 1994 Oral S-adenosyl-L-methionine (SAMe) administration enhances bile salt conjugation with taurine in patients with liver cirrhosis. Scand. J. Clin. Lab. Invest. 54: 459-464.

• Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck-Radosavljevic M 2003 Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52: 879-885. *

• Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ 2003 Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J. Lab. Clin. Med. 142: 385-390. *

• Auguet T, Vidal F, Lopez-Dupla M, Broch M, Gutierrez C, Olona M, Oltra C, Aguilar C, Gonzalez E, Quer JC, Sirvent JJ, Richart C 2008 A study on the TNF-alpha system in Caucasian Spanish patients with alcoholic liver disease. Drug Alcohol Depend. 92: 91-99.

• Auletta M, Oliviero U, Iasiuolo L, Scherillo G, Antoniello S 2000 Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. Angiology 51: 1013-1020.

• Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, Triantos C, Papaxoinis C, Manolakopoulos S, Panani A, Raptis SA 2004 Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology 39: 1623-1630. *

• Bachli EB, Schuepbach RA, Maggiorini M, Stocker R, Mullhaupt B, Renner EL 2007 Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications. Liver Int. 27: 475-484. *

• Bader TR, Beavers KL, Semelka RC 2003 MR imaging features of primary sclerosing cholangitis: patterns of cirrhosis in relationship to clinical severity of disease. Radiology 226: 675-685. *

• Bambha K, Kim WR, Pedersen RA, Bida JP, Kremers WK, Kamath PS 2008 Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 57: 814-820.

• Banares R, Nunez O, Escudero M, Fernandez C, Vaquero J, Beceiro I, Echenagusia A, Clemente G, Santos L 2005 Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology 41: 566-571. *

• Bazarah SM, Peltekian KM, McAlister VC, Bitter-Suermann H, MacDonald AS 2004 Utility of MELD and Child-Turcotte-Pugh scores and the Canadian waitlisting algorithm in predicting short-term survival after liver transplant. Clin. Invest. Med. 27: 162-167.

• Ben-Ari Z, Schafer Z, Sulkes J, Manhaim V, Tur-Kaspa R, Fainaru M 2002 Alterations in serum leptin in chronic liver disease. Dig. Dis. Sci. 47: 183-189. *

• Biancofiore G, Bindi ML, Romanelli AM, Boldrini A, Bisa M, Esposito M, Urbani L, Catalano G, Mosca F, Filipponi F 2005 Fast track in liver transplantation: 5 years' experience. Eur. J. Anaesthesiol. 22: 584-590.

• Bilbao I, Armadans L, Lazaro JL, Hidalgo E, Castells L, Margarit C 2003 Predictive factors for early mortality following liver transplantation. Clin. Transplant. 17: 401-411. *

• Bosch J, Thabut D, Bendtsen F, D'amico G, Albillos A, Gonzalez Abraldes J, Fabricius S, Erhardtsen E, De Franchis R 2004 Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 127: 1123-1130. *

• Breidert M, Zimmermann TF, Schneider R, Ehninger G, Brabant G 2004 Ghrelin/leptin-imbalance in patients with primary biliary cirrhosis. Exp. Clin. Endocrinol. Diabetes 112: 123-126.

• Broome U, Eriksson LS, Sundin U, Sundqvist KG 1992 Decreased in vitro production of tumor necrosis factor in primary biliary cirrhosis patients. Scand. J. Gastroenterol. 27: 124-128.

• Brown KA, Moonka D 2003 Liver transplantation. Curr. Opin. Gastroenterol. 19: 259-263.

• Brown RS Jr, Kumar KS, Russo MW, Kinkhabwala M, Rudow DL, Harren P, Lobritto S, Emond JC 2002 Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl. 8: 278-284. *

• Bruix J 2003 Hepatocellular carcinoma. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 31-33. October 17 - 19. *

• Bruix J, Sala M, Llovet JM 2004 Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S179-S188. *

• Bush DA, Hillebrand DJ, Slater JM, Slater JD 2004 High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 127 (5 Suppl. 2): S189-S193. *

• Caradonna P, Costamagna G, Benedetti G, Gentiloni N, Gasbarrini GB 1996 Chronic pancreatitis prevalence in liver cirrhosis. Morphological and functional study. Ital. J. Gastroenterol. 28: 91-94.

• Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R 2004 Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 40: 652-659. *

• Cardenas A, Gines P, Uriz J, Bessa X, Salmeron JM, Mas A, Ortega R, Calahorra B, De Las Heras D, Bosch J, Arroyo V, Rodes J 2001 Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 34: 671-676. *

• Carrillo-Esper R, Gonzalez-Avila D, Uribe-Rios M, Mendez-Sanchez N 2008 Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Ann. Hepatol. 7: 87-90.

• Casa C, Arnaud JP, Serra-Maudet V, Georgeac G, Kanane S, Ronceray J 1993 Mesocaval anastomosis in the treatment of recurring hemorrhage caused by portal hypertension. J. Chir. (Paris) 130: 517-521.

• Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H 2000 Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31: 7-11. *

• Cheong JY, Lee KM, Cho SW, Won JH, Kim JK, Wang HJ, Hahm KB, Kim JH 2005 Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol. Res. 32: 127-133.

• Christensen E 2004 Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? J. Hepatol. 41: 344-350. *

• Christou L, Pappas G, Falagas ME 2007 Bacterial infection-related morbidity and mortality in cirrhosis. Am. J. Gastroenterol. 102: 1510-1517. *

• Chung H, Kudo M, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y 2006 A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatol. Res. 34: 124-129.

• Colle I, Van Vlierberghe H 2003 Diagnosis and therapeutic problems of primary sclerosing cholangitis. Acta Gastroenterol. Belg. 66: 155-159.

• Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, Ravaioli M, La Barba G, Cavallari A, Bolondi L, Pinna AD 2005 Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J. Hepatol. 43: 310-316. *

• da Silveira EB 2006 Outcome of cirrhotic patients undergoing cholecystectomy: applying Bayesian analysis in gastroenterology. J. Gastroenterol. Hepatol. 21: 958-962. *

• Degre D, Bourgeois N, Boon N, Le Moine O, Louis H, Donckier V, El Nakadi I, Closset J, Lingier P, Vereerstraeten P, Gelin M, Adler M 2004 Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl. Int. 17: 31-38.

• Deschenes M, Villeneuve JP, Dagenais M, Fenyves D, Lapointe R, Pomier-Layrargues G, Roy A, Willems B, Marleau D 1997 Lack of relationship between preoperative measures of the severity of cirrhosis and short-term survival after liver transplantation. Liver Transpl. Surg. 3: 532-537.

• Dias Teixeira MC, de Fatima Gomes de Sa Ribeiro M, Strauss E 2005 A new insight into the differences among non-cirrhotic and cirrhotic patients using the liver disease quality of life instrument (LDQOL). Ann. Hepatol. 4: 264-271. *

• Duman DG, Tuney D, Bilsel S, Benli F, Karan S, Avsar E, Ozdogan O, Tozun N 2005 Octreotide in liver cirrhosis: a salvage for variceal bleeding can be a gunshot for kidneys. Liver Int. 25: 527-535. *

• Durand F 2006 Risk scores in cirrhotic patients: from non-transplant surgery to transplantation and back. J. Hepatol. 44: 620-621. *

• Durand F, Valla D 2005 Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J. Hepatol. 42 Suppl. 1: S100-S107. *

• Duvoux C, Radier C, Roudot-Thoraval F, Maille F, Anglade MC, Van Nhieu JT, Rosa I, Hospitel S, Abd-Alsamad I, Sitruk V, Seror O, Ziol M, Blondon H, Dhumeaux D, Richardet JP 2004 Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis. Hepatology 40: 1370-1378. *

• Edwards EB, Harper AM 2001 Application of a continuous disease severity score to the OPTN liver waiting list. Clin. Transpl. 2001: 19-24.

• Epstein SK, Freeman RB, Khayat A, Unterborn JN, Pratt DS, Kaplan MM 2004 Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl. 10: 418-424. *

• Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M, Trevisani F, for the Italian Liver Cancer (ITALICA) group 2006 Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am. J. Gastroenterol. 101: 524-532. *

• Faust TW, Sorrell MF 1997 The role of the transjugular intrahepatic portal-systemic shunt in the management of variceal bleeding. Clin. Liver Dis. 1: 85-98, xi.

• Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Gines P, Arroyo V 2007 Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133: 818-824. *

• Fernandez-Aguilar JL, Bondia Navarro JA, Santoyo Santoyo J, Suarez-Munoz MA, Perez-Daga A, Ramirez Plaza C, Mera Velasco S, de la Fuente Perucho A 2003 Calibrated portacaval H-graft shunt in variceal hemorrhage. Long-term results. Hepatogastroenterology 50: 2000-2004.

• Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, Cardenas A, Guevara M, Sort P, Jimenez W, Bataller R, Arroyo V, Rodes J 2001 A prognostic model for predicting survival in cirrhosis with ascites. J. Hepatol. 34: 46-52. *

• Fernandez-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutierrez ML, Lledo JL, Santander C, Fernandez TP, Tomas E, Cacho G, Walker JM 2004 Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. 24: 477-483. *

• Festi D, Capodicasa S, Sandri L, Colaiocco-Ferrante L, Staniscia T, Vitacolonna E, Vestito A, Simoni P, Mazzella G, Portincasa P, Roda E, Colecchia A 2005 Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels. World J. Gastroenterol. 11: 142-148. *

• Festi D, Capodicasa S, Vestito A, Mazzella G, Roda E, Vitacolonna E, Petrolati A, Angelico M, Colecchia A 2004 Breath tests with stable isotopes: have they a role in liver transplantation? Eur. Rev. Med. Pharmacol. Sci. 8: 55-58.

• Fisher L, Fisher A 2007 Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin. Gastroenterol. Hepatol. 5: 513-520.

• Flisiak R, Wiercinska-Drapalo A, Prokopowicz D 2000 Antibodies against M2-antigen in differential diagnosis of primary biliary cirrhosis. Pol. Merkuriusz. Lek. 8: 373-375.

• Flores-Rendon AR, Gonzalez-Gonzalez JA, Garcia-Compean D, Maldonado-Garza HJ, Garza-Galindo AA 2008 Model for end stage of liver disease (MELD) is better than the Child-Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding. Ann. Hepatol. 7: 230-234. *

• Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J 2002 Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 8: 1165-1174. *

• Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J,Couzigou P, de Ledinghen V 2006 Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403-408. *

• Freeman RB, Rohrer RJ, Katz E, Lewis WD, Jenkins R, Cosimi AB, Delmonico F, Friedman A, Lorber M, O'Connor K, Bradley J 2001 Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time. Liver Transpl. 7: 173-178. *

• Funk GC, Doberer D, Osterreicher C, Peck-Radosavljevic M, Schmid M, Schneeweiss B 2005 Equilibrium of acidifying and alkalinizing metabolic acid-base disorders in cirrhosis. Liver Int. 25: 505-512. *

• Furrer K, Deoliveira ML, Graf R, Clavien PA 2007 Improving outcome in patients undergoing liver surgery. Liver Int. 27: 26-39. *

• Garcia Ruiz P, Canora Lebrato J, Diez Ruiz A, Fuchs D, Wachter H 2004 Soluble interleukin-2 and tumor necrosis factor receptor in liver cirrhosis. Relationship with clinical severity and prognosis. Med. Clin. (Barc.) 122: 441-443.

• Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE 2004 Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S194-S205. *

• Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R 2000 Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int. J. Biol. Markers 15: 226-230.

• Giannini E, Botta F, Fumagalli A, Malfatti F, Testa E, Chiarbonello B, Polegato S, Bellotti M, Milazzo S, Borgonovo G, Testa R 2004 Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients? Liver Int. 24: 465-470. *

• Gilroy RK, Lynch SV, Strong RW, Kerlin P, Balderson GA, Stuart KA, Crawford DH 2000 Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis. Liver Transpl. 6: 749-752. *

• Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C, Macias MA, Rendon P, Diaz F, Fernandez-Gutierrez C, Martin-Herrera L 2004 Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int. 24: 437-445. *

• Golovnova EV, Il'chenko LIu, Tsaregorodtseva TM, Serova TI, Gudkova RV, Shepeleva SD, Tkachev VD 2003 Primary biliary cirrhosis: 12-year experience in observation. Ter. Arkh. 75: 26-30.

• Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR 2004 Treatment endpoints for advanced cholangiocarcinoma. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 4-5. *

• Gow PJ, Chapman RW 2000 Liver transplantation for primary sclerosing cholangitis. Liver 20: 97-103. *

• Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, Kim S, Lazarovici D, Jensen DM, Busuttil RW, Martin P 2000 Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease - the LDQOL 1.0. Am. J. Gastroenterol. 95: 3552-3565. *

• Hanck C, Manigold T, Bocker U, Kurimoto M, Kolbel CB, Singer MV, Rossol S 2001 Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut 49: 106-111. *

• Hartmann IJ, Groeneweg M, Quero JC, Beijeman SJ, de Man RA, Hop WC, Schalm SW 2000 The prognostic significance of subclinical hepatic encephalopathy. Am. J. Gastroenterol. 95: 2029-2034. *

• Hattori E, Okumoto K, Adachi T, Takeda T, Ito J, Sugahara K, Watanabe H, Saito K, Saito T, Togashi H, Kawata S 2003 Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol. Res. 27: 309-314.

• Hay JE 1998 Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Liver Transpl. Surg. 4 (5 Suppl. 1): S9-S17.

• Heidelbaugh JJ, Sherbondy M 2006 Cirrhosis and chronic liver failure: part II. Complications and treatment. Am. Fam. Physician 74: 767-776. *

• Heller J, Kristeleit H, Brensing KA, Woitas RP, Spengler U, Sauerbruch T 1999 Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. Scand. J. Gastroenterol. 34: 297-302. *

• Herold C, Regn S, Ganslmayer M, Ocker M, Hahn EG, Schuppan D 2002 Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis? Dig. Dis. Sci. 47: 2669-2673. *

• Herrero JI, Espana A, Quiroga J, Sangro B, Pardo F, Alvarez-Cienfuegos J, Prieto J 2005 Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 11: 1100-1106. *

• Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J 2005 De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 11: 89-97. *

• Huang MA, Marrero JA 2002 Hepatocellular carcinoma. Curr. Opin. Gastroenterol. 18: 345-350.

• Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD 2006 Proposal of a modified cancer of the liver Italian program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am. J. Gastroenterol. 101: 975-982. *

• Huo TI, Lee SD, Lin HC 2008 Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int. 28: 606-613. *

• Huo TI, Lin HC, Hsia CY, Wu JC, Lee PC, Chi CW, Lee SD 2007 The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am. J. Gastroenterol. 102: 1920-1930. *

• Huo TI, Wang YW, Yang YY, Lin HC, Lee PC, Hou MC, Lee FY, Lee SD 2007 Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int. 27: 498-506. *

• Huo TI, Wu JC, Lee PC, Chang FY, Lee SD 2004 Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int. 24: 210-215. *

• Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Huang YH, Lee PC, Chang FY, Lee SD 2004 Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl. 10: 1507-1513. *

• Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD 2005 Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J. Hepatol. 42: 826-832. *

• Huo TI, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, Chang FY, Lee SD 2004 Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am. J. Gastroenterol. 99: 1479-1487. *

• Iannuzzi C, Cozzolino G, Negro G 1993 Elective cholecystectomy in selected cirrhotic patients. Acta Chir. Belg. 93: 147-150.

• Ishikawa A, Nishida H, Baba T, Mitamura K 2000 Evaluation of balloon-occluded hepatic venography with carbon dioxide for portography and correlation between retrograde portogram and liver function in patients with liver cirrhosis. Hepatol. Res. 18: 239-251.

• Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M 2008 Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134: 1908-1916. *

• Ito K, Shiraki K, Sakai T, Yoshimura H, Nakano T 2005 Portal hypertensive colopathy in patients with liver cirrhosis. World J. Gastroenterol. 11: 3127-3130. *

• Jacob DA, Neumann UP, Bahra M, Langrehr JM, Neuhaus P 2006 Liver transplantation for primary biliary cirrhosis: retrospective analysis of results at a single center. Dtsch. Med. Wochenschr. 131: 2327-2332.

• Jen-Eing J, Jung-Fa T, Lee-Yea C, Mei-Shang H, Zu-Yau L, Min-Yuh H, Shin-Chern C, Wan-Lung C, Liang-Yen W, Ming-Lung Y, Chia-Yen D, Jan-Gowth C 2007 Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 9: 987-992.

• Jonas E, Naslund E, Freedman J, Befrits R, Blomqvist L, Siosteen AK, Jacobsson H, Hultcrantz R 2006 Measurement of parenchymal function and bile duct flow in primary sclerosing cholangitis using dynamic Tc-HIDA SPECT. J. Gastroenterol. Hepatol. 21: 674-681. *

• Kalaitzakis E, Simren M, Olsson R, Henfridsson P, Hugosson I, Bengtsson M, Bjornsson E 2006 Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. Scand. J. Gastroenterol. 41: 1464-1472. *

• Kanwal F, Hays RD, Kilbourne AM, Dulai GS, Gralnek IM 2004 Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am. J. Gastroenterol. 99: 1726-1732. *

• Keeffe EB, Davis GL 2004 Advances in Liver Disease: Highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42. *

• Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK 2005 Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J. Gastroenterol. Hepatol. 20: 873-881. *

• Khan TT, Reddy KS, Johnston TD, Lo FK, Shedlofsky S, Grubb S, Ranjan D 2002 Transjugular intrahepatic portosystemic shunt migration in patients undergoing liver transplantation. Int. Surg. 87: 279-281.

• Kim WR, Dickson ER 2000 Timing of liver transplantation. Semin. Liver Dis. 20: 451-464. *

• Kim WR, Poterucha JJ, Wiesner RH, LaRusso NF, Lindor KD, Petz J, Therneau TM, Malinchoc M, Dickson ER 1999 The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 29: 1643-1648. *

• Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Benson JT, Krom RA, Dickson ER 2000 Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transpl. 6: 489-494. *

• Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S 2007 Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am. J. Gastroenterol. 102: 1939-1946. *

• Krieger S, Jauss M, Jansen O, Stiehl A, Sauer P, Geissler M, Theilmann L, Krieger D 1997 MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. J. Hepatol. 27: 121-126. *

• Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T 2004 Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40: 1396-1405. *

• Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F 2006 Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit. Care 10: R108. *

• Launois B, Meunier B, Foglia M, Khelif D, Spiliopoulos Y, Stasik C, Lakehal M, Guezennec L, Camus C, Messner M 1996 200 first hepatic transplantation at the Rennes University Hospital. Chirurgie 121: 207-214.

• Leandros E, Albanopoulos K, Tsigris C, Archontovasilis F, Panoussopoulos SG, Skalistira M, Bramis C, Konstandoulakis MM, Giannopoulos A 2008 Laparoscopic cholecystectomy in cirrhotic patients with symptomatic gallstone disease. ANZ J. Surg. 78: 363-365. *

• Lencioni R, Della Pina C, Bartolozzi C 2005 Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom. Imaging 30: 401-408. *

• Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, Tseng SC, Lin WP, Chen WT, Sheen IS 2007 Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J. Hepatol. 46: 816-826. *

• Liu Q, Duan ZP, Ha da K, Bengmark S, Kurtovic J, Riordan SM 2004 Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39: 1441-1449. *

• Llado L, Figueras J, Memba R, Xiol X, Baliellas C, Vazquez S, Ramos E, Torras J, Rafecas A, Fabregat J, Lama C, Jaurrieta E 2002 Is MELD really the definitive score for liver allocation? Liver Transpl. 8: 795-798. *

• Loehe F, Schauer RJ 2005 Surgical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Rev. Allergy Immunol. 28: 167-174. *

• Look MP, Riezler R, Reichel C, Brensing KA, Rockstroh JK, Stabler SP, Spengler U, Berthold HK, Sauerbruch T 2000 Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at the level of gamma-cystathionase? Scand. J. Gastroenterol. 35: 866-872. *

• Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH 1997 Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl. Surg. 3: 628-637.

• Lyra AC, Soares MB, da Silva LF, Fortes MF, Silva AG, Mota AC, Oliveira SA, Braga EL, de Carvalho WA, Genser B, Dos Santos RR, Lyra LG 2007 Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J. Gastroenterol. 13: 1067-1073. *

• Maier KP 2006 Natural course of primary sclerosing cholangitis (PSC). Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 5. *

• Mandell MS, Lezotte D, Kam I, Zamudio S 2002 Reduced use of intensive care after liver transplantation: patient attributes that determine early transfer to surgical wards. Liver Transpl. 8: 682-687. *

• Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, Loguercio C, Apolone G, Niero M, Abbiati R; Italian Study Group for quality of life in cirrhosis 2001 Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 120: 170-178. *

• Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M 1996 Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 23: 1084-1092. *

• Margarit C, Escartin A, Castells L, Vargas V, Allende E, Bilbao I 2005 Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 11: 1242-1251. *

• Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Gloria H, Marinho R, Tavora I, Ramalho F, de Moura MC 2006 Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 26: 680-687. *

• Mendoza-Sanchez F, Haro-Haro FJ, Sandoval-Alvarado J, Zepeda-Gonzalez A, Herrera-Rodriguez R, Bassols-Ricardez A 2007 Orthotopic liver transplantation: results at a single center. Cir. Cir. 75: 281-285.

• Meneu-Diaz JC, Moreno Gonzalez E, Moreno Elola-Olaso A, Lopez EV, Nuno Vazquez J, Jimenez C, Turrion V, Loinaz C, Gomez R, Abradelo M 2003 Liver recipients undergoing hepatic transplantation and subsequent retransplantation: a comparison between clinical characteristics. Hepatogastroenterology 50: 2143-2148.

• Mercado MA, Chan C, Zenteno-Guichard G, Vasques M, Hernandez J, Orozco H 1999 Results of surgical treatment (modified Sugiura-Futagawa operation) of portal hypertension associated to complete splenomesoportal thrombosis and cirrhosis. HPB Surg. 11: 157-162.

• Merkel C, Bolognesi M, Bellon S, Sacerdoti D, Bianco S, Amodio P, Gatta A 1992 Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. J. Hepatol. 15: 299-303.

• Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A 2000 The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 32: 930-934. *

• Merkel C, Zoli M, Siringo S, van Buuren H, Magalotti D, Angeli P, Sacerdoti D, Bolondi L, Gatta A 2000 Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am. J. Gastroenterol. 95: 2915-2920. *

• Merli M, Nicolini G, Angeloni S, Gentili F, Attili AF, Riggio O 2004 The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am. J. Gastroenterol. 99: 1959-1965. *

• Milkiewicz P, Saksena S, Cardenas T, Mills CO, Elias E 2000 Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis. Liver 20: 330-334.

• Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W 2005 Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 11: 960-966. *

• Moller S, Norgaard A, Henriksen JH, Frandsen E, Bendtsen F 2004 Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology 40: 811-819. *

• Montano-Loza A, Vazquez-Ballesteros E, Meza-Junco J, Villalobos-Zapata I, Olivera-Martinez M 2006 Seropositivity for Chlamydia pneumoniae in patients with primary biliary cirrhosis. Gastroenterol. Hepatol. 29: 113-117.

• Moran S, Rodriguez-Leal G, Marin-Lopez E, Arista J, Poo JL, Vargas-Vorackova F, Kershenobich D, Uribe M 1996 Primary biliary cirrhosis: clinical features and survival of a Mexican population. Rev. Gastroenterol. Mex. 61: 212-219.

• Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D, Valla DC 2004 Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 24: 457-464. *

• Nakamura H, Tanaka E, Kaneko M, Iwakawa M, Hori T, Ikebukuro K, Amagai T, Ohkawa H 2001 The clinical importance of the trimethadione tolerance test as a method for quantitative assessment of hepatic functional reserve in patients with biliary atresia. J. Clin. Pharm. Ther. 26: 417-424. *

• Nemes B, Sarvary E, Sotonyi P, Gerlei Z, Doros A, Galffy Z, Fehervari I, Fazakas J, Jaray J, Kobori L 2005 Factors in association with sepsis after liver transplantation: the Hungarian experience. Transplant. Proc. 37: 2227-2228. *

• Neuberger J 2004 Liver transplantation for autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 82-83. *

• Neuberger J, Thorburn D 2005 MELD - Moving steadily towards equality, equity, and fairness. Liver Transpl. 11: 585-587.

• Newsome PN, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, Plevris JN 2000 Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment. Pharmacol. Ther. 14: 1295-1301. *

• Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, Kanda T, Kawano S, Hiramatsu N, Hayashi N, Hori M 2006 Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am. J. Gastroenterol. 101: 70-75. *

• No authors listed 1993 The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J. Hepatol. 17: 227-235.

• Odeh M 2007 Relationship between circulating levels of tumour necrosis factor-alpha and Child-Pugh scores in liver cirrhosis. Int. J. Clin. Pract. 61: 519. *

• Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi I 2005 In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J. Clin. Pharmacol. 45: 1221-1229. *

• Okamoto K, Mimura K, Murawaki Y, Yuasa I 2005 Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J. Gastroenterol. Hepatol. 20: 1102-1108. *

• Ono K, Kokubu S, Hidaka H, Watanabe M, Nakazawa T, Saigenji K 2005 Risk factors of delay in restoration of hepatic reserve capacity and local recurrence after radiofrequency ablation therapy for hepatocellular carcinoma (HCC). Hepatol. Res. 31: 172-177.

• Oren R, Sikuler E, Wong F, Blendis LM, Halpern Z 2000 The effects of hypothyroidism on liver status of cirrhotic patients. J. Clin. Gastroenterol. 31: 162-163.

• Orlando A, D'Antoni A, Camma C, Albanese M, Livraghi T, Torzilli G, Virdone R, Sciarrino E, Simonetti RG, Maringhini A, Pagliaro L, Cottone M 2000 Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am. J. Gastroenterol. 95: 2921-2927. *

• Ormarsdottir S, Ljunggren O, Mallmin H, Olsson R, Prytz H, Loof L 2002 Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function. J. Intern. Med. 252: 537-541. *

• Orozco H, Mercado MA, Chan C, Ramos-Gallard G, Galvez-Trevino R, Salgado-Nesme N, Cisneros De-Ajuria R, Javier Anthon F 2002 Current role of surgery for the treatment of portal hypertension. Ann. Hepatol. 1: 175-178. *

• Oya H, Sato Y, Yamamoto S, Takeishi T, Kobayashi T, Hatakeyama K 2004 Living related donor liver transplantation for primary sclerosing cholangitis with hepatocellular carcinoma and Crohn's disease: a case report. Transplant. Proc. 36: 2297-2298. *

• Panasiuk A, Zak J, Panasiuk B, Prokopowicz D 2007 Increase in expression of monocytic tissue factor (CD142) with monocytes and blood platelet activation in liver cirrhosis. Blood Coagul. Fibrinolysis 18: 739-744.

• Panzera P, Cicco G, Memeo R, Catalano G, Greco L, Staffieri F, Lupo L, Memeo V 2005 MELD predictive value of alterations of brain perfusion during liver transplantation. Transplant. Proc. 37: 2622-2625. *

• Parra Blanco JA, Juanco Pedregal C, Silvan Delgado M 1995 Changed hepatic vein flow in patients with cirrhosis. A Doppler study of hepatic veins in patients with cirrhosis. Rev. Esp. Enferm. Dig. 87: 621-623.

• Pascual S, Zapater P, Such J, Garcia-Herola A, Sempere L, Irurzun J, Palazon JM, Carnicer F, Perez-Mateo M 2006 Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int. 26: 673-679. *

• Perri F, Marras RM, Ricciardi R, Quitadamo M, Andriulli A 2004 13C-breath tests in hepatology (cytosolic liver function). Eur. Rev. Med. Pharmacol. Sci. 8: 47-49.

• Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, McIlroy K, Donaghy AJ, McCall JL 2008 Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology 48: 557-566.

• Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger MH, Condat B, Farges O, Chagneau C, de Ledinghen V, Francoz C, Sauvanet A, Vilgrain V, Belghiti J, Durand F, Valla D 2006 Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 44: 1308-1316. *

• Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ, Hayes PC 2000 Serum hyaluronan - a non-invasive test for diagnosing liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 12: 1121-1127.

• Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, Rapaccini GL 2005 Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl. 11: 1117-1126. *

• Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, Fernandez-Zertuche M, Rodriguez-Fragoso L, Uribe M 2006 Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized,lactulose-controlled study. Ann. Hepatol. 5: 281-288. *

• Poonawala A, Nair SP, Thuluvath PJ 2000 Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32: 689-692. *

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP 2005 Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16. *

• Prall RT, Lindor KD, Wiesner RH, LaRusso NF 2000 Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103.

• Prediletto R, Catapano G, Bottai M, Bauleo C, Mannucci F, Filipponi F, Sbragia P, Caramella D, Bartolozzi C 2004 Role of the chest radiograph in the preoperative assessment of the pulmonary function in patients with cirrhosis candidates to liver transplant. Radiol. Med. (Torino) 108: 320-334.

• Rais-Jalali GA, Sagheb MM, Daniali F, Behzadi S, Roozbeh J, Nikeghbalian S, Bahador A, Salahi H, Malek-Hosseini SA 2007 Acute renal failure in the first 100 orthotopic liver transplant patients in southern Iran. Exp. Clin. Transplant. 5: 710-712.

• Ramirez FC, Colon VJ, Landan D, Grade AJ, Evanich E 2007 The effects of the number of rubber bands placed at each endoscopic session upon variceal outcomes: a prospective, randomized study. Am. J. Gastroenterol. 102: 1372-1376. *

• Ramirez FC, Hakim S, Tharalson EM, Shaukat MS, Akins R 2005 Feasibility and safety of string wireless capsule endoscopy in the diagnosis of esophageal varices. Am. J. Gastroenterol. 100: 1065-1071. *

• Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D 2003 Prometheus - a new extracorporeal system for the treatment of liver failure. J. Hepatol. 39: 984-990. *

• Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, Bezzi M, Attili AF, Merli M 2005 Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J. Hepatol. 42: 674-679. *

• Rocca P, Cocuzza E, Rasetti R, Rocca G, Zanalda E, Bogetto F 2003 Predictors of psychiatric disorders in liver transplantation candidates: logistic regression models. Liver Transpl. 9: 721-726. *

• Romero-Gomez M, Grande L, Camacho I 2004 Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 39: 939-943. *

• Romero-Gomez M, Ramos-Guerrero R, Grande L, De Teran LC, Corpas R, Camacho I, Bautista JD 2004 Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J. Hepatol. 41: 49-54. *

• Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR 2004 Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J. Hepatol. 40: 897-903. *

• Sala M, Forner A, Varela M, Bruix J 2005 Prognostic prediction in patients with hepatocellular carcinoma. Semin. Liver Dis. 25: 171-180.

• Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, Bru C, Bruix J 2004 Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40: 1352-1360. *

• Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F 2004 Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40: 629-635. *

• Sandhu BS, Luketic VA 2006 Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849. *

• Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C 2003 Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 125: 1042-1052. *

• Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke-Schlieker W, Hellerbrand C, Kuth J, Schanz S, Kahl S, Fleig WE, Sauerbruch T; German Study Group for the Primary Prophylaxis of Variceal Bleeding 2004 Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 40: 65-72. *

• Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, Sauerbruch T 2003 Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am. J. Gastroenterol. 98: 1167-1174. *

• Schinella M, Guglielmi A, Veraldi GF, Boni M, Frameglia M, Caputo M 1993 Evaluation of the liver function of cirrhotic patients based on the formation of monoethylglycine xylidide (MEGX) from lidocaine. Eur. J. Clin. Chem. Clin. Biochem. 31: 553-557.

• Schoniger-Hekele M, Ramskogler K, Hartl D, Lesch OM, Muller C 2006 Exclusion of trisialo-transferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease? Wien. Med. Wochenschr. 156: 216-222.

• Schrumpf E, Boberg KM 2002 Endoscopic treatment for primary sclerosing cholangitis? J. Hepatol. 36: 278-279. *

• Schuppan D, Jia JD, Brinkhaus B, Hahn EG 1999 Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104. *

• Sen S, Biswas PK, Biswas J, Das TK, De BK 1999 Primary pulmonary hypertension in cirrhosis of liver. Indian J. Gastroenterol. 18: 158-160.

• Sethar GH, Ahmed R, Zuberi BF, Afsar S 2004 Frequency of Helicobacter pylori antibodies in porto-systemic encephalopathy. J. Coll. Physicians Surg. Pak. 14: 530-533.

• Shahid M, Johnson J, Nightingale P, Neuberger J 2005 Nutritional markers in liver allograft recipients. Transplantation 79: 359-362.

• Shetty K, Rybicki L, Carey WD 1997 The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology 25: 1049-1053. *

• Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M 2005 A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130. *

• Shrestha R, McKinley C, Showalter R, Wilner K, Marsano L, Vivian B, Everson GT 1997 Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver Transpl. Surg. 3: 166-173.

• Shypulin VP 2007 Liver cirrhosis and therapy issues. Lik. Sprava. 1-2: 36-40.

• Sieders E, Peeters PM, TenVergert EM, de Jong KP, Porte RJ, Zwaveling JH, Bijleveld CM, Gouw AS, Slooff MJ 2002 Graft loss after pediatric liver transplantation. Ann. Surg. 235: 125-132. *

• Silveira MG, Lindor KD 2008 High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J. Hepatol. 48: 692-694. *

• Singh N, Gayowski T, Wagener MM 1997 Intensive care unit management in liver transplant recipients: beneficial effect on survival and preservation of quality of life. Clin. Transplant. 11: 113-120.

• Singh N, Gayowski T, Wagener MM, Marino IR 1997 Depression in patients with cirrhosis. Impact on outcome. Dig. Dis. Sci. 42: 1421-1427. *

• Singh N, Wannstedt C, Keyes L, Wagener MM, De Vera M, Cacciarelli TV, Gayowski T 2004 Impact of evolving trends in recipient and donor characteristics on cytomegalovirus infection in liver transplant recipients. Transplantation 77: 106-110.

• Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH 2004 Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 10: 648-653. *

• Spahr L, Lambert JF, Rubbia-Brandt L, Chalandon Y, Frossard JL, Giostra E, Hadengue A 2008 Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology 48: 221-229.

• Stanley AJ, MacGregor IR, Dillon JF, Bouchier IA, Hayes PC 1996 Neutrophil activation in chronic liver disease. Eur. J. Gastroenterol. Hepatol. 8: 135-138.

• Strasser S, Sheil AG, Gallagher ND, Waugh R, McCaughan GW 1993 Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: a comparison of complications and outcome. J. Gastroenterol. Hepatol. 8: 238-243.

• Stuart KA, Fletcher LM, Clouston AD, Lynch SV, Purdie DM, Kerlin P, Crawford DH 2000 Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation. Hepatology 32: 1200-1207. *

• Su CW, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Lee PC, Lee SD, Wu JC 2008 Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int. Mar 11 [Epub ahead of print]. *

• Sumskiene J, Kupcinskas L, Pundzius J, Sumskas L 2005 Prognostic factors for short and long-term survival in patients selected for liver transplantation. Medicina (Kaunas) 41: 39-46.

• Tacke F, Fiedler K, Trautwein C 2007 A simple clinical score predicts high risk for upper gastrointestinal hemorrhages from varices in patients with chronic liver disease. Scand. J. Gastroenterol. 42: 374-382. *

• Tagle AM, Vega DJ, Scavino LY, Luna CE 2004 Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis: report of a case. Rev. Gastroenterol. Peru 24: 349-352.

• Takahashi H, Kato A, Onodera K, Suzuki K 2006 Fasting plasma ghrelin levels reflect malnutrition state in patients with liver cirrhosis. Hepatol. Res. 34: 117-123.

• Talwalkar JA, Kim WR, Rosen CB, Kamath PS, Wiesner RH 2003 Effect of minimal listing criteria on waiting list registration for liver transplantation: a process-outcome analysis. Mayo Clin. Proc. 78: 431-435. *

• Talwalkar JA, Seaberg E, Kim WR, Wiesner RH 2000 Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child-Pugh score. National Institutes of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Group. Liver Transpl. 6: 753-758. *

• Tang KS, Lee CM, Teng HC, Huang MJ, Huang CS 2008 UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis. Biochem. Biophys. Res. Commun. 366: 643-648. *

• Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R 2006 Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J. Hepatol. 45: 280-289. *

• Thalheimer U, Triantos C, Samonakis D, Patch D, Burroughs AK, Riddell A, Perry D 2005 Endogenous heparinoids in acute variceal bleeding. Gut 54: 310-311. *

• Thomson AW, Satoh S, Nussler AK, Tamura K, Woo J, Gavaler J, van Thiel DH 1994 Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clin. Exp. Immunol. 95: 83-90. *

• Tojimbara T, Fuchinoue S, Nakajima I, Kimikawa M, Kitajima K, Ishida H, Koyama I, Utsumi K, Sannomiya A, Tsuji K, Tanaka K, Takasaki K, Agishi T 2000 Factors affecting survival after living-related liver transplantation. Transpl. Int. 13 Suppl. 1: S136-S139.

• Tran TT 2003 Liver transplantation: a clinical update. 54th Annual Meeting of the American Association for the Study of Liver Diseases.

• Trevisani F, Magini G, Santi V, Morselli-Labate AM, Chiara Cantarini M, Anna Di Nolfo M, Del Poggio P, Benvegnu L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giovanni Giannini E, Caturelli E, Bernardi M; for the Italian Liver Cancer (ITA LI.CA) Group 2007 Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am. J. Gastroenterol. 102: 1022-1031. *

• Tripathi D, Therapondos G, Lui HF, Johnston N, Webb DJ, Hayes PC 2004 Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am. J. Gastroenterol. 99: 390-394. *

• Trotter JF, Suhocki PV, Rockey DC 1998 Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score. Am. J. Gastroenterol. 93: 1891-1894. *

• Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, Yang C, Chen PC, Wu CS 2006 Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 43: 673-681. *

• Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG 2008 Malnutrition in end stage liver disease: recommendations and nutritional support. J. Gastroenterol. Hepatol. 23: 527-533. *

• Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA 2001 Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann. Intern. Med. 134: 89-95. *

• Ulukaya S, Arikan C, Aydogdu S, Ayanoglu HO, Tokat Y 2003 Immediate tracheal extubation of pediatric liver transplant recipients in the operating room. Pediatr. Transplant. 7: 381-384.

• Valla DC 2002 Hepatic vein thrombosis (Budd-Chiari syndrome). Semin. Liver Dis. 22: 5-14.

• van Dam GM, Gips CH, Reisman Y, Maas KW, Purmer IM, Huizenga JR, Verbaan BW 1999 Major clinical events, signs and severity assessment scores related to actual survival in patients who died from primary biliary cirrhosis. A long-term historical cohort study. Hepatogastroenterology 46: 108-115.

• van Hoek B, Lindor KD, Murtaugh PA, Harrison JM, Krom RA, Wiesner RH, Nagorney DM 1994 The role of portosystemic shunts for variceal bleeding in the liver transplantation era. Arch. Surg. 129: 683-688.

• Vangeli M, Patch D, Terreni N, Tibballs J, Watkinson A, Davies N, Burroughs AK 2004 Bleeding ectopic varices-treatment with transjugular intrahepatic porto-systemic shunt (TIPS) and embolisation. J. Hepatol. 41: 560-566. *

• Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, Mayer AD, Buckels JA, McMaster P, Neuberger J, Mirza DF 2003 Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75: 1983-1988.

• Verbeeck RK 2008 Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharmacol. Sep 2 [Epub ahead of print].

• Wensing G, Hoffmann K, Heidemann HT 1993 Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis. Z. Gastroenterol. 31: 15-19.

• Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R; United Network for Organ Sharing Liver Disease Severity Score Committee 2003 Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124: 91-96. *

• Wiesner RH 2003 Indications. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 109-110. October 17 - 19. *

• Witzke O, Baumann M, Patschan D, Patschan S, Mitchell A, Treichel U, Gerken G, Philipp T, Kribben A 2004 Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J. Gastroenterol. Hepatol. 19: 1369-1373. *

• Yaghi C, Sharara AI, Rassam P, Moucari R, Honein K, Boujaoude J, Slim R, Noun R, Abdul-Baki H, Khalifeh M, Ramia S, Sayegh R 2006 Hepatocellular carcinoma in Lebanon: etiology and prognostic factors associated with short-term survival. World J. Gastroenterol. 12: 3575-3580. *

• Yagmur E, Schnyder B, Scholten D, Schirin-Sokhan R, Koch A, Winograd R, Gressner AM, Trautwein C, Wasmuth HE 2006 Elevated concentrations of fecal calprotectin in patients with liver cirrhosis. Dtsch. Med. Wochenschr. 131: 1930-1934.

• Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F 2007 Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin. Biochem. 40: 651-655. *

• Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP 2004 Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 39: 230-238. *

• Yoneyama K, Miyagishi K, Kiuchi Y, Shibata M, Mitamura K 2002 Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. J. Gastroenterol. 37: 1028-1034. *

• Yoo HY, Edwin D, Thuluvath PJ 2003 Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am. J. Gastroenterol. 98: 1395-1399. *

• Yoo HY, Thuluvath PJ 2005 Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States. Liver Int. 25: 536-541. *

• Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G 2000 Cholestatic liver diseases and health-related quality of life. Am. J. Gastroenterol. 95: 497-502. *

• Yu AS, Keeffe EB 2003 Patient selection criteria for liver transplantation. Minerva. Chir. 58: 635-648.

• Zaman A, Hapke R, Flora K, Rosen HR, Benner K 1999 Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am. J. Gastroenterol. 94: 3292-3296. *

• Zamirian M, Aslani A, Shahrzad S 2007 Left atrial volume: a novel predictor of hepatopulmonary syndrome. Am. J. Gastroenterol. 102: 1392-1396.

• Zapata R, Innocenti F, Sanhueza E, Humeres R, Rios H, Suarez L, Palacios JM, Rius M, Hepp J 2004 Predictive models in cirrhosis: correlation with the final results and costs of liver transplantation in Chile. Transplant. Proc. 36: 1671-1672. *

• Zhang Y, Liu D, Ma Q, Dang C, Wei W, Chen W 2006 Factors influencing the prevalence of gallstones in liver cirrhosis. J. Gastroenterol. Hepatol. 21: 1455-1458. *

• Zoli M, Iervese T, Merkel C, Bianchi G, Magalotti D, Marchesini G, Gatta A, Pisi E 1993 Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. J. Hepatol. 17: 56-61.

• Zoli M, Merkel C, Magalotti D, Gueli C, Grimaldi M, Gatta A, Bernardi M 2000 Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am. J. Gastroenterol. 95: 503-508. *

Number of references = 255

www psc-literature.org